Drug intelligence / Profile preview

opigolix

Development stage: Phase 2
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

Opigolix (ASP1707) is an orally administered small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist. It was developed by Astellas Pharma for the treatment of endometriosis-associated pelvic pain and rheumatoid arthritis. By antagonizing the GnRH receptor, opigolix reduces levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased production of sex hormones such as estradiol. This mechanism aims to alleviate symptoms associated with estrogen-dependent conditions like endometriosis while minimizing hypoestrogenic side effects such as bone loss compared to traditional GnRH agonists[1][2][3][5][6][7].

Other names: opigolixASP1707ASP-1707ASP 1707

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on opigolix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on opigolix.

Explore the full profile